Form 8-K - Current report:
SEC Accession No. 0001104659-25-054712
Filing Date
2025-05-30
Accepted
2025-05-30 11:42:46
Documents
16
Period of Report
2025-05-29
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2516608d1_8k.htm   iXBRL 8-K 57336
2 EXHIBIT 99.1 tm2516608d1_ex99-1.htm EX-99.1 25106
3 EXHIBIT 99.2 tm2516608d1_ex99-2.htm EX-99.2 16650
4 EXHIBIT 99.3 tm2516608d1_ex99-3.htm EX-99.3 6630
5 EXHIBIT 99.4 tm2516608d1_ex99-4.htm EX-99.4 6301
  Complete submission text file 0001104659-25-054712.txt   292722

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA acur-20250529.xsd EX-101.SCH 3020
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE acur-20250529_lab.xml EX-101.LAB 34239
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE acur-20250529_pre.xml EX-101.PRE 22362
18 EXTRACTED XBRL INSTANCE DOCUMENT tm2516608d1_8k_htm.xml XML 3580
Mailing Address 616 N. NORTH COURT, SUITE 120 . PALATINE IL 60067
Business Address 616 N. NORTH COURT, SUITE 120 PALATINE IL 60067 847-705-7709
ACURA PHARMACEUTICALS, INC (Filer) CIK: 0000786947 (see all company filings)

EIN.: 110853640 | State of Incorp.: NY | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-10113 | Film No.: 251008625
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)